Patients must have histopathologically /cytologically confirmed advanced solid tumor which is refractory to standard therapeutic options, or for which there are no standard therapeutic options, or for whom paclitaxel is an appropriate palliative treatment option (patients for whom paclitaxel or nab-paclitaxel are established treatment options with a proven survival benefit in first line will be excluded)
Histologically confirmed advanced solid tumors with no clear curative treatment options available after at least 1 prior systemic anticancer therapy.
Has failed (refractory) or relapsed after no more than 2 prior regimens, and for whom for whom no other standard therapy options are available.
no standard therapeutic options available (to be supplemented)
Previously treated for advanced cancer with no additional therapy options available known to prolong survival.
The patient has given written informed consent after the nature of the study and alternative treatment options have been explained
Dose escalation:\r\n* Any locally advanced or metastatic solid tumor malignancy with no curative treatment options available
Progression on standard therapy, not a candidate for further chemotherapy or patient declines other options
Must have failed or be unable to tolerate or refused other available Food and Drug Administration (FDA) approved effective therapies; NOTE: patients should not have other treatment options considered curative
Have been informed of other treatment options
Patients for whom other curative or established standard-of-care therapeutic options with acceptable morbidity exist
Patients with options for treatment that are known to be curative are not eligible.
Patients must have disease that has relapsed after or is refractory to at least 2 lines of standard therapy; the remaining standard treatment options are unlikely to be effective in the opinion of the treating physician, or patient is felt to be ineligible for such therapies or the patient refuses such therapies; patients who have undergone autologous stem cell transplant are eligible as long as they meet all other criteria
Have been informed of other treatment options
Formal evaluation by the Liver Tumor Program at University of Taxes Southwestern (UTSW) and/or review at the Liver Tumor Board: all patients should be fairly and prudently informed of their treatment options; to this end, all patients must be evaluated before brachytherapy treatment for discussion and consideration of other options for treatment of liver cancer including surgical resection
Have been informed of other treatment options and is not a candidate for standard treatment options or stem cell transplant at the time of enrollment
Patients with options for treatment that are known to be curative are not eligible
Patients who do not have other options of treatment, based on consensus recommendation of the multidisciplinary SSRS tumor board; patients will have an appropriate medical oncologist for their disease
No available curative treatment options, a limited prognosis of several months to < 2 years anticipated survival with currently available therapies, and progressive or relapsed disease
Have been informed of other treatment options
Male or female subjects with AML with no available curative treatment options using currently available therapies
CAPMATINIB INCLUSION CRITERIA: Prior treatment with at least one Food and Drug Administration (FDA)-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
CERITINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
REGORAFENIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
ENTRECTINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
No known effective therapy options are available
Patients with curative treatment options
Previously treated for advanced cancer and there are no curative therapy options available
Previously treated for advanced cancer with no additional therapy options available known to prolong survival
Progression by RANO criteria following all standard treatment options with known survival benefit
Patients must have received at least one course of chemotherapy consisting of a platinum doublet and must have no acceptable standard treatment options
Patients must have failed standard therapy and at the time of study entry have recurrent, progressive or refractory disease with no known curative options
Subjects must have primary or metastatic liver malignancies for which are surgically unresectable, and exhausted all standard therapeutic options to be eligible for this study
Patients with rapidly advancing systemic disease, especially those without good options of systemic treatment for their disease outside the CNS (Cohort D)
no standard therapy options
3. Morphologically documented relapsed/refractory AML as defined by World Health Organization (WHO) criteria after at least 1 prior therapy for AML with the exception of hydroxyurea, and not felt to have curative treatment options per treating physician, or the patients themselves are unwilling to consider curative treatment options.
Have been informed of other treatment options
Histologically or cytologically proven diagnosis of hematologic malignancies for whom all standard therapy options have failed
A disease expert at the study site must have a detailed discussion with the patient of other treatment options which either have been approved by the FDA or are part of or relevant to the standard care of patients with B-CLL/SLL in the multiply relapsed setting
Histologic proof of cancer which is now not amenable to alternative curative or clearly superior standard treatment options
Has relapsed or refractory disease and no standard treatment options as determined by locally or regionally available standards of care and treating physician's discretion
Patient is fit to receive the randomization options for which he is being considered
Recurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator.
Histologic proof of cancer which is now not amenable to curative standard treatment options
Have been informed of other treatment options
Patients who declined standard therapies or whose physicians determined they were not suitable for standard therapy options are eligible
Advanced or metastatic colorectal cancer with no curative options available and progression on previous standard therapy, including an EGFR inhibitor if KRAS wild-type
Have been informed of other treatment options.
Must have advanced disease and no standard treatment options as determined by locally/regionally available standards of care and treating physician's discretion
Patient with extensive systemic disease and without reasonable systemic treatment options.
Participants must have adenocarcinoma of the prostate that is metastatic or unresectable and for which standard curative options do not exist
Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.
Subject has no available or declines curative treatment options such as allogeneic stem cell transplant (SCT) and has limited prognosis (< 2 years survival) with currently available therapies
Have been informed of other treatment options
Phase Ia: Patients may have de novo metastatic disease, or documented progression despite any number of prior therapies; patients must have no curative or other effective therapeutic options available
(Arm A) relapsed or refractory CLL/SLL and require treatment in the opinion of the Investigator. Subject must have relapsed following or be refractory to standard treatments such as fludarabine based regimens (F, FC, FR, FCR) or alkylator (chlorambucil, bendamustine) based regimens. In addition, there are no other curative options, and the subject has exhausted options that would be considered standard of care, or
(Arm B) relapsed or refractory NHL and require treatment in the opinion of the Investigator. Subject must have histologically documented diagnosis of NHL as defined in the World Health Organization classification scheme, except as noted in the exclusion criteria. Subject must have relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens. In addition, there are no other curative options, and the subject has exhausted options that would be considered standard of care. Subjects with other lymphoproliferative diseases can be considered in consultation with the Abbott medical monitor.
Patient must not have curative options available (e.g. a single metastatic focus in the liver in a patient with MCRC eligible for metastasectomy).
Randomized cohort: resistant or intolerant to prior ruxolitinib therapy. Documentation by the Investigator that the patient has exhausted available treatment options (eg, resistant or intolerant to hydroxyurea, etc).
Subjects with pathologically documented AML that has failed standard treatment, or subjects without prior therapy who refuse standard treatment options
Have been informed of other treatment options.
Therapeutic Options: Patients must be ineligible or inappropriate for other treatment regimens known to have curative potential.
Relapsed or refractory disease (as defined below) for which patients are ineligible for or have exhausted standard therapeutic options that would be considered standard of care
Pre-existing limitations on care options, (Do Not Attempt Resuscitation Orders, etc).
Disease that has progressed despite other available standard treatment options, based on what is clinically indicated according to the investigator's clinical and medical judgment, including:
Have been informed of other treatment options
Other therapeutic and palliative options have been exhausted
Declined all standard treatment options
Have not had their initial doctor consultation to discuss treatment options
Ineligible for or have exhausted standard therapeutic options
Male or female patients, ages 12 years and older, with relapsed or refractory B-ALL who have failed, or are intolerant to, any established therapy; or for whom no other treatment options are available.
Metastatic disease that is not amenable to curative surgery or radiation
3. Part B, must have a histologically or cytologically documented diagnosis of esophageal or gastric carcinoma, nasopharyngeal carcinoma (NPC), endometrial cancer, soft tissue sarcoma, or other orphan tumor who have received at least one line of standard systemic therapy for their respective tumor type in the metastatic setting with progressive locally advanced or metastatic disease that is not amenable to definitive local therapy with curative intent;
Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumor that is not amenable for treatment with curative intent as follows:
Has metastatic disease defined as disseminated disease distant to the initial/primary site of diagnosis, and/or must have locally recurrent disease that has been previously treated (with either surgery, radiotherapy, or systemic therapy), and is not amenable to either curative surgery, radiotherapy, or concurrent chemoradiotherapy treatment.
Participant has histological confirmation of a locally advanced or metastatic solid tumor of a type associated with Prolactin Receptor (PRLR) expression that has progressed on prior treatment, is not amenable to treatment with curative intent, and has no other therapy options known to provide clinical benefit or the subject is ineligible for such therapies.
Participants must have disease that is not amenable to curative resection
Advanced disease is defined as metastatic disease or locally advanced disease that is not amenable to surgery or radiotherapy with curative intent
All disease must be amenable to embolization in one or two procedures
Has histologically or cytologically confirmed triple negative breast carcinoma that is either metastatic (stage IV of the TNM classification) or locally recurrent and not amenable to local curative treatment.
Locally advanced disease must not be amenable to resection with curative intent
Patients must have disease that is not amenable to potentially curative resection; either primary in-situ (or locally-recurrent) tumor must be present and, in the opinion of radiation oncology, be amenable to radiation therapy as planned in the protocol or an extrapancreatic lesion which in the opinion of the radiation oncologist is amenable to radiation; each case will be discussed at gastrointestinal (GI) tumor board with multidisciplinary team
Part B7: Must have a diagnosis of HR+ and HER2- breast cancer; have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease; no previous treatment or currently receiving 1 of the following treatments for locoregionally recurrent or metastatic breast cancer (chemotherapy, endocrine therapy, CDK4/6 inhibitor, and PI3K and/or mTOR inhibitor)
Adenocarcinoma of the stomach or GEJ with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy
Diagnosis of advanced or metastatic cancer not amenable to curative therapy
Has a pathologically documented unresectable advanced NSCLC disease not amenable to curative therapy
Patients must have recurrent or metastatic HNSCC stage III/IV that is not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Has locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation.
Patients with stage IV metastatic cancer and/or cancer that is not amenable to surgery (i.e. must be curative intent; locally advanced is acceptable if completely resected)
Male or female advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
Patients must have advanced disease that is not amenable to transplant or resection
Histologically or cytologically confirmed adenocarcinoma of the breast with evidence of metastatic disease (stage IV) or locally advanced disease, not amenable to surgery or radiation with curative intent
Unresectable or metastatic breast cancer; locally recurrent disease must not be amenable to any local treatment with curative intent; metastatic disease must be demonstrated either radiographically or histologically
Histologically or cytologically proven diagnosis of breast cancer with evidence of metastatic or locally advanced disease, not amenable to resection or radiation therapy with curative intent
Advanced disease (Masaoka staging) not amenable to curative treatment
Locally advanced or metastatic disease not amenable to surgery
Pathologically confirmed advanced pancreatic cancer defined as non-operable in a curative intent, locally recurrent, or metastatic disease
Metastatic disease not amenable to surgical resection with curative intent
Barcelona Clinic Liver Cancer (BCLC) Stage B or C disease not amenable to or progressing after loco-regional therapy and not amenable to a curative treatment approach
Women with histologically or cytologically confirmed breast cancer with evidence of metastatic or locally advanced disease not amenable to any local therapy with curative intent.
Adult men and women (? 18 years of age) with histologically confirmed diagnosis of metastatic and/or advanced solid tumors not amenable to curative treatment by surgery.
Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent
Confirmed diagnosis of ER-positive, HER2-negative advanced breast cancer, not amenable to curative therapy
Pathologically confirmed diagnosis of stage IIIB/IV recurrent squamous cell NSCLC defined as not amenable to local curative therapy (surgery, radiation, or chemoradiation), and refractory to systemic therapy OR Pathologically or radiologically (fulfilling non-invasive criteria) confirmed diagnosis of HCC not amenable to resection (partial hepatectomy or liver transplantation) or local therapy with curative intent (e.g. radiofrequency ablation) and must not be a liver transplant candidate as defined according to Milan criteria
Have advanced (not amenable to potentially curative surgery) or metastatic RCC
Disease that is amenable to serial biopsies
Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC
Metastatic disease or locally-advanced disease not amenable to curative intent treatment
Males or females with advanced (locoregionally recurrent or metatstatic) breast cancer not amenable to curative therapy
Phase I: Patients must have histologically confirmed breast cancer (metastatic breast cancer [MBC]) that is human epidermal growth factor receptor 2 (HER2/neu) negative (as determined by local pathology or reference laboratory), and have disease that is metastatic (stage IV [TxNxM1]) or locally advanced and not amenable to potentially curative surgical resection (eg, clinical stage IIIB-C)
Locally advanced breast cancer that is not amenable to curative radiation or surgical cure and/or metastatic disease appropriate for systemic single cytotoxic chemotherapy
The subject has disease that is not amenable to a curative treatment approach.
The tumor is unresectable and not amenable to curative therapy.
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Adult women (? 18 years of age) with metastatic or recurrent locally advanced BC, not amenable to curative treatment by surgery or radiotherapy, with objective evidence of disease progression.
Participant must have metastatic or advanced NSCLC (Stage IIIB or IV) that is not amenable to surgical resection or radiation or chemoradiation with curative intent at time of study screening.
Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease, both progressing after at least 6 months of hormonal therapy for ER+ breast cancer
Women (?18 years of age) with metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy.
Nasopharyngeal carcinoma basket\r\n* Metastatic or locally recurrent disease not amenable to curative intent treatment\r\n* Any number of prior therapies, including 0
Merkel cell carcinoma basket \r\n* Metastatic or locally recurrent disease not amenable to curative intent treatment\r\n* Any number of prior therapies, including 0
Pleural mesothelioma basket\r\n* Metastatic or locally recurrent disease not amenable to curative intent treatment\r\n* Refractory to platinum and pemetrexed systemic therapy\r\n* Any number of prior therapies
Histologically or cytologically confirmed breast cancer with evidence of metastatic or locally advanced disease not amenable to resection or radiation therapy with curative intent and who have progressed during treatment with at least one prior hormonal therapy
Newly diagnosed locally advanced tumour which requires upfront systemic chemotherapy but is still amenable to curative treatment (i.e. chemotherapy followed by definitive chemoradiotherapy)
Locally recurrent tumor which is amenable to curative resection (as deemed by a local surgeon or multidisciplinary team)
Patient has advanced (loco regionally recurrent not amenable to curative therapy, e.g. surgery and/or radiotherapy, or metastatic) breast cancer. Patients may be:
Adult Asian women with locoregionally recurrent or metastatic disease not amenable to curative therapy
Patient has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy
Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease
Patients with metastatic cancer and/or cancer that is not amenable to surgery (i.e. must be curative intent; locally advanced is acceptable)
Histologically documented triple-negative adenocarcinoma of the breast that is inoperable locally advanced or metastatic and is not amenable to resection with curative intent
Any previous therapy, including chemotherapy or hormonal or targeted therapy, for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy and/or radiation treatment for locally advanced triple negative adenocarcinoma, provided all treatments were completed greater than or equal to (>/=) 6 months prior to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with curative intent
Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease.
Women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy
Metastatic or locally advanced disease that is not amenable to resection or radiation with curative intent.
Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy.
Patients must have histological or cytological diagnosis of melanoma with progressive locally advanced or metastatic disease that is not amenable to definitive local therapy with curative intent
Locally advanced/metastatic NSCLC, not amenable to curative surgery or radiotherapy
Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy.
Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC
Have locally advanced disease not amenable to curative treatment by surgery or metastatic disease. In addition, participants must fulfill 1 of the following criteria:
Subject must have advanced or metastatic squamous NSCLC that is not amenable to surgical resection or radiation with curative intent at time of study Screening.
Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent in adult patients with: NSCLC, TNBC, HR+ breast cancer, recurrent platinum sensitive ovarian cancer, UC, CRPC, and other advanced solid tumors with a BRCA or ATM gene defect
Histologically and cytologically proven locally advanced or metastatic pancreatic adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent, and has failed or is not eligible for available chemotherapies
Disease which is amenable to curative local therapy
PK expansion patients: Histologic documentation of locally unresectable or metastatic renal cell carcinoma not currently amenable to surgery, radiation, or other therapy with curative intent
Patients with metastatic or locally advanced, unresectable breast cancer not amenable to curative treatment by surgery or radiotherapy
Subjects must have metastatic and/or locally advanced or locally recurrent disease that is not amenable to curative surgical resection; If a patient declines surgery, they may be considered for this study
Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.
Histologically-confirmed MBC not deemed amenable to curative surgery or curative radiation therapy
Metastatic disease not amenable to surgical resection with curative intent
Patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.
Recurrent or metastatic disease that is not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Subject has histologically confirmed locally advanced or unresectable Stage IIIB (not amenable to receive curative treatments such as chemo-radiation)/IV or metastatic NSCLC.
Histological or cytological diagnosis of triple negative breast cancer (TNBC) with evidence of a) metastatic or b) locally recurrent advanced disease that is not amenable to resection or radiotherapy with curative intent.
Patients with carcinoma of the cervix must have advanced disease not amenable to curative surgery and/or radiation therapy
Disease that is currently not amenable to curative surgical intervention.
Females with a histologically confirmed diagnosis of breast cancer that is metastatic or locally advanced (locally advanced tumors must not be amenable to surgery or radiation therapy with curative intent) with the following pathological characteristics determined locally: estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 (HER-2) negative, and Ki67 (a tumor marker) ? 15% determined by the central study laboratory
Have evidence of persistent, recurrent, or progressive disease for which there is no known or established treatment available with curative intent, after at least one course of systemic therapy for locally advanced or metastatic disease , including chemotherapy, targeted therapy (small molecule or antibody based), or hormonal therapy
Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy
Women or men aged =>18 years with histologically documented triple-negative breast cancer (TNBC) or HR+/HER2- adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to resection with curative intent
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Must have recurrent or metastatic disease that is not amenable to therapy with curative intent (surgery and/or radiation therapy with or without chemotherapy).
Measurable disease that is amenable to curative intent therapy, or amenable to standard of care systemic/palliative therapy (e.g. platinum containing chemotherapy, cetuximab, pembrolizumab or other approved options)
Patients with metastatic and/or advanced solid tumors or lymphomas not amenable to curative treatment by surgery.
The participant has disease that is not amenable to a curative approach
Women (?18 years of age) with metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy.
Adult women > 18 years of age with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy
Has locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Histologically confirmed recurrent or metastatic HNSCC (oral cavity, pharynx, or larynx) that is stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
Prior treatment with >1 line of chemotherapy for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
Experienced PD on >2 endocrine therapies for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent
Patients must have disease that is not amenable to potentially curative resection or ablative techniques or that has recurred following ablative techniques. In addition, disease must not be amenable to transhepatic arterial chemoembolization (TACE) or must have progressed on TACE. Patients must not be candidates for liver transplantation.
Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Not a candidate for potentially curative therapy at the time of enrollment
Participants must have histologically confirmed adenoid cystic carcinoma with evidence of recurrent or metastatic disease not amenable to potentially curative surgery or radiotherapy
Has a known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Subjects with tumor amenable to potentially curative therapy per principal investigator (PI)
Be eligible and reasonably fit to undergo potentially curative resection
Patients must have disease that is not amenable to potentially curative resection
Patients must have disease that is not amenable to potentially curative resection
Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Subjects not seeking or receiving potentially curative therapies for cancer.
Ability to undergo potentially curative chemotherapy plus radiotherapy
Patients must have disease that is not amenable to potentially curative resection; patients must have received, been intolerant of or refused at least one line of chemotherapy
Patient's cancer must have relapsed after or failed to respond to frontline curative therapy or there must not be other potentially curative treatment options available
Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation; HCC patients must have progressed on, been intolerant to, or refused prior sorafenib therapy; patients with BTC must have received, been intolerant of or refused at least one line of chemotherapy
Patients must have potentially curable disease
Patients with a history of a prior malignancy who have undergone potentially curative therapy with no evidence of that disease for five years, or patients who are deemed low risk for recurrence by his/her treating physician are permitted to enroll
Subjects with tumor amenable to potentially curative therapy
Candidate for known standard therapy for the patient’s disease that is potentially curative
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy; subjects will be excluded if this is their first relapse and they have recurred > 6 months from completion of primary (adjuvant) chemotherapy
Must not be a candidate for potentially curative therapy or standard-of-care approved therapy
Histologically or cytologically confirmed, or clinically diagnosed based on currently accepted standards, cancer metastatic to the liver or HCC that is not amenable at the time of enrollment to resection, transplant or other potentially curative therapy.
Primary HCC amenable to resection, transplant or other potentially curative therapy.
Received and failed potentially curative chemotherapeutic regimens (e.g., ABVD, Stanford V, or BEACOPP)
Must not be a candidate for potentially curative therapy or standard-of-care approved therapy.
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Known standard therapy for the patient’s disease that is potentially curative
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy; EXCEPTION: For platinum-resistant ovarian cancer, because nab-paclitaxel has known benefit, patients who may benefit from standard single agent chemotherapy are also eligible to participate
COHORT I (DOSE ESCALATION): known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Patients who are candidates (eligible and willing) for standard and/or potentially curative treatments are not eligible
Patients who have received prior chemoradiation, radiation, and/or surgery in the potentially curative setting are eligible as long as 3 months has elapsed since the end of the potentially curative treatment ended
Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
Have no curative therapy available.
Subjects for whom potentially curative anticancer therapy is available.
Patients must have disease that is not amenable to potentially curative resection, and must not have metastatic disease
Patients must have recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy
Known standard therapy for the patient’s disease that is potentially curative
Patients must have no known curative therapy available
The patient has undergone potentially curative therapy for all prior malignancies,
Received one or more lines of chemotherapy, which must include prior treatment with a platinum agent and must not be amenable to potentially curative radiotherapy or surgery
Known standard therapy for the patient’s disease that is potentially curative or proven capable of extending life expectancy
Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy
Patients who have recurrences that are amenable to potentially curative treatment with radiation therapy or surgery
Patients must have recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy
Subjects for whom potentially curative anticancer therapy is available.
Disease eligible for potentially curative treatment with standard chemotherapy, surgical resection, or chemoradiotherapy
Subjects for whom potentially curative anticancer therapy is available.
Candidate for potentially curative therapies in the opinion of the investigator.
Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation; for Cohorts A and D patients must have progressed on, been intolerant to, or refused prior sorafenib therapy; Cohort E patients must have received at least one line of chemotherapy for BTC
Patients with isolated recurrences (vaginal, pelvic, or para-aortic) that are amenable to potentially curative treatment with radiation therapy or surgery
Patients with tumor amenable to potentially curative therapy
Potentially curative therapy is available
Known standard therapy for the patient’s disease that is potentially curative or proven capable of extending life expectancy
Patients for whom potentially curative anticancer therapy is available
Candidate for known standard therapy for the patient’s disease that is potentially curative
Patients must have recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy
Liver disease must not be amenable to potentially curative surgical resection
Patients must have disease that is potentially amenable to curative resection as reviewed by the Medical University of South Carolina (MUSC) Gastrointestinal (GI) Tumor Board
Patients must have disease that is potentially amenable to curative resection as reviewed by the Medical University of South Carolina (MUSC) Gastrointestinal (GI) Tumor Board
Patients with tumor amenable to potentially curative therapy as assessed by the investigator
Patients with tumor amenable to potentially curative therapy as assessed by the investigator
Patients who have isolated recurrences (vaginal, pelvic, or paraaortic) that are amenable to potentially curative treatment with radiation therapy or surgery
Subjects for whom potentially curative anticancer therapy is available
Subject is eligible for a potentially curative therapy.
Histologically or cytologically confirmed mCRC not amenable to potentially curative resection with at least one measurable metastatic lesion, as defined by RECIST v1.1
Subjects must have failed, be intolerant to, or be ineligible for any potentially curative approved treatment, irrespective of line of therapy
The subject had at least one prior line of systemic therapy and has a tumor, which is not amenable to potentially curative surgical resection.
Patients for whom potentially curative antineoplastic therapy is available
Patients must have disease that is not amenable to potentially curative resection or ablative techniques; in addition, disease must not be amenable to or have progressed on transhepatic arterial chemoembolization (TACE); patients must not be considered potential candidates for liver transplantation; this determination will be made after hepatobiliary surgical input at the NCI multidisciplinary conference
Patients with cancer potentially curable by surgical excision alone or patients who have not received therapy that might be considered standard and potentially curable
Be eligible and reasonably fit to undergo potentially curative resection
For patients with lymphomas that are considered potentially curable, all curative attempts should be exhausted before the patient is considered eligible for this study
If the patient is a survivor of a prior invasive cancer, all of the following criteria must apply: \r\n* Patient has undergone potentially curative therapy for all prior malignancies\r\n* No evidence of active/recurrent disease
